285814 20260401151453.0 10.59249/CTWM1697 doi pmid:41918512 pmid pmc:PMC13023422 pmc 0044-0086 ISSN 1551-4056 ISSN DZNE-2026-00350 English 610 Ali, Mehak 0 Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery. New Haven, Conn. 2026 [Verlag nicht ermittelbar] article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1775049203_19920 PUB:(DE-HGF) ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote Parkinson's disease (PD) is a neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to significant motor dysfunction. Current treatments stabilize dopamine levels but fail to address underlying neuronal apoptosis, highlighting the need for novel approaches. Although chrysoeriol, a 3'-O-methoxy flavone and luteolin derivative, is well-documented for its anti-cancer, anti-diabetic, antioxidant, and anti-inflammatory properties, its neuroprotective potential in PD, particularly in vivo, remains largely unexplored. This study fills a critical gap by being the first to systematically assess chrysoeriol's neuroprotective effects in a PD mouse model. We evaluated the effects of 5 mg/kg chrysoeriol administered intraperitoneally (IP) for 14 days in an acute 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Behavioral tests showed notable recovery, as chrysoeriol eliminated deficits in motor function, coordination, and balance, as assessed by the pole test, forced swim test, and tail suspension test. It also mitigated exploratory and locomotor deficits in the open field test, and the Y-maze test revealed improved spatial and learning memory. Hematoxylin and eosin staining indicated a significant reduction in neuronal damage across key brain regions. qPCR analysis showed reduced 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity, downregulation of α-synuclein, and an improved Bcl-2/Bax ratio. These findings suggest chrysoeriol may protect against MPP+-induced apoptosis in mice, potentially via the PI3K/Akt signaling pathway, and reduces mitochondrial damage by downregulating α-synuclein. 353 - Clinical and Health Care Research (POF4-353) G:(DE-HGF)POF4-353 POF4-353 POF IV 0 Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de BAX Other Bcl-2 Other Neuroprotective Other Parkinson’s disease Other chrysoeriol Other α-Synuclein Other alpha-Synuclein NLM Chemicals Neuroprotective Agents NLM Chemicals Flavones NLM Chemicals Animals MeSH Apoptosis: drug effects MeSH alpha-Synuclein: metabolism MeSH Neuroprotective Agents: pharmacology MeSH Neuroprotective Agents: therapeutic use MeSH Male MeSH Parkinson Disease: drug therapy MeSH Parkinson Disease: metabolism MeSH Mice MeSH Mice, Inbred C57BL MeSH Disease Models, Animal MeSH Recovery of Function: drug effects MeSH Flavones: pharmacology MeSH Neuroprotection: drug effects MeSH Dopaminergic Neurons: drug effects MeSH Dopaminergic Neurons: metabolism MeSH Mehreen, Mehwish 1 Batool, Saima 2 Khan, Shahrukh 3 Noor, Aneeqa 4 Mumtaz, Sara 5 Zafar, Saima P:(DE-2719)9000358 6 Last author dzne 10.59249/CTWM1697 Vol. 99, no. 1, p. 111 - 126 PERI:(DE-600)2063545-X 1 111 - 126 Yale journal of biology and medicine 99 2026 0044-0086 http://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf Restricted http://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf?subformat=pdfa pdfa Restricted Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 6 P:(DE-2719)9000358 DE-HGF Gesundheit Neurodegenerative Diseases G:(DE-HGF)POF4-350 G:(DE-HGF)POF4-353 G:(DE-HGF)POF4 G:(DE-HGF)POF4-300 G:(DE-HGF)POF Clinical and Health Care Research 0 JCR StatID:(DE-HGF)0100 StatID YALE J BIOL MED : 2022 2025-11-12 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2025-11-12 DBCoverage StatID:(DE-HGF)0300 StatID Medline 2025-11-12 DBCoverage StatID:(DE-HGF)0320 StatID PubMed Central 2025-11-12 DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2025-11-12 DBCoverage StatID:(DE-HGF)1190 StatID Biological Abstracts 2025-11-12 DBCoverage StatID:(DE-HGF)0160 StatID Essential Science Indicators 2025-11-12 WoS StatID:(DE-HGF)0113 StatID Science Citation Index Expanded 2025-11-12 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2025-11-12 DBCoverage StatID:(DE-HGF)1030 StatID Current Contents - Life Sciences 2025-11-12 DBCoverage StatID:(DE-HGF)1050 StatID BIOSIS Previews 2025-11-12 DBCoverage StatID:(DE-HGF)0501 StatID DOAJ Seal 2024-02-19T11:40:40Z DBCoverage StatID:(DE-HGF)0500 StatID DOAJ 2024-02-19T11:40:40Z Peer Review StatID:(DE-HGF)0030 StatID DOAJ : Anonymous peer review, Double anonymous peer review 2024-02-19T11:40:40Z Creative Commons Attribution-NonCommercial CC BY-NC (No Version) LIC:(DE-HGF)CCBYNCNV V:(DE-HGF) DOAJ 2024-02-19T11:40:40Z IF < 5 StatID:(DE-HGF)9900 StatID 2025-11-12 I:(DE-2719)1440011-1 AG Zerr Translational Studies and Biomarker 0 journal EDITORS VDBINPRINT I:(DE-2719)1440011-1 UNRESTRICTED